For years, the tech industry has offered a moral trade-off: the vast energy consumption and cultural disruption of large-scale artificial intelligence are the necessary costs for a future of radical discovery. This rhetoric—suggesting that "slop" videos and chatbots are merely the byproduct of a quest to cure cancer or solve climate change—is now being tested as the industry’s leaders pivot toward "AI co-scientists." These systems are designed to move beyond simple clerical assistance, such as drafting papers or summarizing literature, toward the autonomous generation of hypotheses and experimental design.
The prestige of this pursuit reached a high-water mark with Google DeepMind’s Nobel Prize in 2024, awarded for AlphaFold’s ability to predict protein structures. That success transformed scientific AI from a niche academic interest into a competitive frontier. Google has since released dedicated co-scientist tools, while Anthropic has introduced features specifically tuned for biological research, signaling a shift from general-purpose models to specialized instruments for the laboratory.
OpenAI has identified the creation of an autonomous researcher as its "North Star," recently launching GPT-Rosalind as the first in a series of specialized scientific models. The ambition is to create a digital peer capable of navigating the complexities of the scientific method with minimal human intervention. Whether these agents can truly replicate the intuition and rigor of a human scientist remains an open question, but for the companies building them, the stakes are as much about institutional legitimacy as they are about technical progress.
With reporting from MIT Technology Review.
Source · MIT Technology Review
